Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 402-480-0 | CAS number: 111850-26-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant guideline study, available as unpublished report, no restrictions, fully adequate for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 988
- Report date:
- 1988
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Details on test material:
- - Name of test material (as cited in study report): FAT 40'279/B
- Lot/batch No.: UO-Vers. 1276/86
- Expiration date of the lot/batch: December 1991
- Stability under test conditions: stable for at least 2 hours
- Storage condition of test material: Room temperature, dark
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Kleintierfarm Madoerin AG, CH 4414 Fuellinsdorf, Switzerland
- Age at pretest: 7-8 weeks
- Weight at pretest: males: 174-194 g, females: 164 - 187 g
- Housing: Individually in Makrolon type-3 cages with standard softwood bedding ('Lignocel', Schill AG, 4132 Muttenz, Switzerland).
- Diet (e.g. ad libitum): Pelleted standard Kliba 343, Batch 72/87 and 73/87 rat maintenance diet ('Kliba', Klingentalmuehle AG, 4303 Kaiseraugst, Switzerland) available ad libitum
- Water (e.g. ad libitum): Community water from Itingen, available ad libitum
- Acclimation period: Seven days under laboratory conditions, after veterinary examination
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 40-70
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 4%
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 10mL/kg bw
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration, homogeneity and stability of the test article/vehicle mixtures were performed prior to the first application (pretest) and at week 3 of treatment. Analysis were performed in the RCC Analytical Laboratory, according to a method supplied by the sponsor.
- Duration of treatment / exposure:
- up to 28 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
50, 200, 1000 mg/kg bw
Basis:
actual ingested
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based upon data received from acute studies and a five-day range finding study (RCC Project 083204).
Examinations
- Observations and examinations performed and frequency:
- - Viability/mortality: Observations for mortality were recorded daily.
- Clinical signs: Signs of toxicity were assessed daily. Descriptions of all abnormalities were recorded and the subsequent progress was monitored.
- Food consumption: The food consumption was recorded once during the acclimatization period and weekly thereafter.
- Body weight: The body weight of each animal was recorded weekly during the acclimatization and treatment period.
- Ophthalmoscopic examinations: Ophthalmoscopic examinations were performed on all animals. A description of any abnormality was recorded. Examinations were performed at termination of treatment. Ten minutes after the application of a mydriatic solution (Dispersa AG, Winterthur / Switzerland) the cornea, lens, anterior chamber, vitreous body and ocular fundus of both eyes were examined under dimmed light using a Heine Miroflex 2 Ophthalmoscope (Eisenhut Vet. AG, Allschwil / Switzerland).
- Clinical laboratory investigations: Blood samples for hematology and clinical biochemistry were collected from all animals under light ether anesthesia. The animals were fasted for 18 hours before blood sampling but water was provided. Blood samples were collected from each animal between the hours of 7.00 and 9.30 a.m. to reduce biological variation caused by circadian rhythms. Blood samples were drawn from the retroorbital plexus. Urine was collected over an 18-hour period into a specimen vial using a metabolism cage, during which time the animals were deprived of food but allowed access to water ad libitum. Parameters being measured for hematology: erythrocyte count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, reticulocyte count, nucleated erythrocytes normoblasts, total leukocyte count, differential leukocyte count, red cell morphology, thromboplastin time, partial thromboplastin time. Parameters being measured for clinical biochemistry: glucose, urea, creatinine, bilirubin, cholesterol, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, calcium, phosphorus, sodium, potassium, chloride, albumin, protein total. Parameters being measured for urinalysis: volume (18 hour), specific gravity, pH, protein, glucose, ketone, bilirubin, blood, nitrite, urobilinogen, urine sediment. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- All animals were necropsied and descriptions of all macroscopic abnormalities were recorded. The following organ weights were recorded on the scheduled date of necropsy: adrenals, heart, kidneys, liver, testes.
HISTOPATHOLOGY: Yes
- Slides of adrenals, heart, kidneys, liver, spleen, stomach and gross lesions (all animals) were collected at terminal sacrifice and from the animals of the control and high-dose groups examined by a pathologist. Upon detection of treatment-related morphologic changes in the organs of any high-dose animal, histologic evaluation of the same organs in all dose groups were performed. - Statistics:
- Univariate one-way analysis of variance was used to assess the significance of intergroup differences. If the variables could be assumed to follow a normal distribution, the Dunnett-test (many to one t-test) based on a pooled variance estimate was applied for the comparison between the treated groups and the control groups. The Steel-test (many-one rank test) was applied when the data could not be assumed to follow a normal distribution. For the overall spontaneous mortality data, the Fisher's exact test for 2x2 tables was applied.Group means were calculated for continuous data and medians were calculated for discrete data (scores).
Results and discussion
Results of examinations
- Details on results:
- - Mortality: No death occurred.
- Clinical signs: Starting with day 3 of the treatment period, all animals of the 200 and 1000 mg/kg bw groups showed yellowish discolored feces. This discoloration was observed in all animals of these groups until termination of treatment. No other signs or symptoms were observed in the animals of the control and test article-treated groups.
- Food consumption: No significant differences in food consumption were observed between the animals of the control and test article-treated groups throughout the treatment period.
- Body weights: No significant differences in body weight gain were observed between the animals of the control and test article-treated groups throughout the treatment period.
- Ophthamlnoscopic examinations: No differences between the control and test article-treated animals were observed.
- Clinical laboratory investigations: The assessment of hematological, biochemical and urinalysis data indicated no changes of toxicological significance at the end of the treatment. All differences in the results of the hematology, clinical biochemistry and urinalysis parameters were considered to be incidental and of normal biological variation
- Organ weights: No significant differences which were related to test article treatment were observed in absolute and relative organ weights between the animals of the test article-treated and control groups. All differences observed were considered to be incidental and of normal biological variation.
- Macroscopic findings: Treatment related macroscopic findings took the form of yellowish discoloration of the stomach mucosa in three rats at the intermediate dose and in eight rats of the high dose group. In one case (No. 17, male group 4), this was accompanied by a red focus. Other gross findings were unremarkable.
- Microscopic findings: There were no microscopic correlates of the grossly observed discoloration of the stomach mucosa, nor could dyestuff particles be identified in the lumen of the organ. In the one case identified above, the gross finding in the stomach was correlated with a focus of minimal erosive gastritis. This finding is considered to be the result of an accidental gavage injury. Other microscopic findings recorded were spontaneous in nature and are within the normal range observed in this age and strain of rat. They may be attributed to subclinical illness, spontaneous congenital abnormalities or physiological status.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Effect level based on clinical symptomps, body weight, food consumption, ophthalmoscopic examination, clinical laboratory investigations, and pathology
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- NOAEL was determined to be 1000 mg/kg/bw.
- Executive summary:
In a GLP compliant repeated toxicity study, performed according to OECD guideline 407, Wistar rats were treated with the test substance (0, 50, 200, and 1000 mg/kg bw) by repeated oral gavage, for a period of 28 days. The study was comprised of four groups, each containing five male and five female rats. No treatment related effects were observed on mortality, clinical signs, food consumption, body weight, ophthalmoscopic examinations, clinical laboratory investigations, organ weights, macroscopic and microscopic findings. The only test substance related finding was yellowish discoloration of the feces and gastric mucosa at the high and intermediate doses. Therefore, the NOAEL was determined to be 1000 mg/kg/bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Vi har mycket webbmaterial på ditt språk, men en del av den här sidan finns bara på engelska. Mer om vår flerspråkighetspolicy finns.
Välkommen till Echas webbplats. Alla funktioner på den här webbplatsen fungerar inte med Internet Explorer 7 (eller tidigare versioner). Det är därför bäst att du uppgraderar till en nyare version.
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.
Läs mer om hur vi använder kakor.